NCARDIA AG

Their core work

Ncardia (formerly Axiogenesis) is a German SME specializing in human iPSC-derived cell models for drug discovery and translational medicine. They provide cell-based assay platforms and metabolism analysis tools that help pharmaceutical and biotech companies screen drug candidates more effectively. Their H2020 work spans cell therapy development for diabetes (ELASTISLET), drug candidate screening (DeCISIoN), and metabolic profiling for translational medicine (METACELL-TM), positioning them at the intersection of cell biology, drug development, and industrial biotech manufacturing.

What they specialise in

How they've shifted over time

Ncardia's H2020 portfolio is concentrated in a narrow 2015–2019 window, making it difficult to identify a strong temporal shift. Their earliest involvement (ELASTISLET, 2015) focused on advanced biomaterials for cell therapy in diabetes — a more fundamental research application. By 2016, both DeCISIoN and METACELL-TM indicate a pivot toward commercial drug screening tools and metabolic analysis platforms, suggesting a move from therapeutic research toward industrialized screening services.

Ncardia appears to be shifting from contributing to fundamental cell therapy research toward building and commercializing scalable drug screening and metabolism analysis platforms — a direction relevant for pharma partnerships.

How they like to work

Ncardia has never coordinated an H2020 project, participating as a partner (2 projects) and third party (1 project). With 18 unique consortium partners across 11 countries, they operate as a specialist contributor brought in for their cell model and assay expertise rather than leading consortia. This pattern is typical of a technology SME that provides a specific capability to larger research teams.

Despite only 3 projects, Ncardia has collaborated with 18 unique partners across 11 countries, indicating they plug into broad European consortia rather than working within a narrow national circle. Their network spans both health and manufacturing pillars.

What sets them apart

Ncardia occupies a niche at the crossroads of cell biology and industrial drug screening — they bring human iPSC-derived cell models into consortium projects that need reliable, scalable biological assays. Their former identity as Axiogenesis, a recognized name in stem cell-derived cardiomyocyte technology, adds credibility. For consortium builders, they offer a commercially oriented SME that can translate academic cell biology into standardized screening platforms.

Highlights from their portfolio

• METACELL-TM
  Largest EC contribution (EUR 556,438) and directly tied to Ncardia's commercial ambitions — the project aimed to position the SME as a European leader in cell metabolism analysis.
• ELASTISLET
  A research-intensive project applying advanced biomaterials (elastin-like recombinamers) to cell therapies for diabetes, showing Ncardia's capacity for fundamental biomedical research contributions.